Search research articles
Contact Us
Filters
Showing results (71-80 of 110) with videos related to
Page
of 11
Sort By:
Drug Safety
|
December 13, 2023
Implementation of a Taxonomy-Based Framework for the Selection of Appropriate Drugs and Outcomes for Real-World Data Signal Detection Studies
Astrid Coste, Angel Ys Wong, Charlotte Warren-Gash, et al.
Clinical Pharmacology and Therapeutics
|
October 24, 2021
Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019
Sini Marika Eskola, Hubertus Gerardus Maria Leufkens, Andrew Bate, et al.
Clinical Pharmacology and Therapeutics
|
December 21, 2025
The Rising Misuse of Pharmacovigilance Reporting Systems: A Threat to Evidence-Based Medicine
Charles Khouri, Alex Hlavaty, Michele Fusaroli, et al.
Drug Safety
|
May 2, 2023
Identifying Safety Subgroups at Risk: Assessing the Agreement Between Statistical Alerting and Patient Subgroup Risk
Olivia Mahaux, Greg Powell, François Haguinet, et al.
Clinical Pharmacology and Therapeutics
|
May 5, 2026
Reply to "A Comment about AI Methods that May Help Advance Pharmacovigilance"
Charles Khouri, Alex Hlavaty, Michele Fusaroli, et al.
Drug Safety
|
March 17, 2026
9<sup>th</sup> ISoP Intelligent Automation Boston Seminar: From Innovation to Impact. Building Trustworthy AI in Pharmacovigilance 4-5 December 2025 | Cambridge, USA & Virtual
Omar Aimer, Tarek A Hammad, Jan Petracek, et al.
British Journal of Clinical Pharmacology
|
February 5, 2026
Through the lens of marketing authorization holders: experience in use of real-world data and real-world evidence in drug development and regulatory submissions in EU
Sini M Eskola, Aleksandar Gigov, Hubertus G M Leufkens, et al.
Drug Safety
|
April 30, 2024
Timing Matters: A Machine Learning Method for the Prioritization of Drug-Drug Interactions Through Signal Detection in the FDA Adverse Event Reporting System and Their Relationship with Time of Co-exposure
Vera Battini, Marianna Cocco, Maria Antonietta Barbieri, et al.
Pharmacoepidemiology and Drug Safety
|
May 10, 2002
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
Eugène P van Puijenbroek, Andrew Bate, Hubert G M Leufkens, et al.
Drug Safety
|
March 13, 2025
Off-the-Shelf Large Language Models for Causality Assessment of Individual Case Safety Reports: A Proof-of-Concept with COVID-19 Vaccines
Andrea Abate, Elisa Poncato, Maria Antonietta Barbieri, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 110) with videos related to
Sort By:
Page
of 11
Drug Safety
|
December 13, 2023
Implementation of a Taxonomy-Based Framework for the Selection of Appropriate Drugs and Outcomes for Real-World Data Signal Detection Studies
Astrid Coste, Angel Ys Wong, Charlotte Warren-Gash, et al.
Clinical Pharmacology and Therapeutics
|
October 24, 2021
Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019
Sini Marika Eskola, Hubertus Gerardus Maria Leufkens, Andrew Bate, et al.
Clinical Pharmacology and Therapeutics
|
December 21, 2025
The Rising Misuse of Pharmacovigilance Reporting Systems: A Threat to Evidence-Based Medicine
Charles Khouri, Alex Hlavaty, Michele Fusaroli, et al.
Drug Safety
|
May 2, 2023
Identifying Safety Subgroups at Risk: Assessing the Agreement Between Statistical Alerting and Patient Subgroup Risk
Olivia Mahaux, Greg Powell, François Haguinet, et al.
Clinical Pharmacology and Therapeutics
|
May 5, 2026
Reply to "A Comment about AI Methods that May Help Advance Pharmacovigilance"
Charles Khouri, Alex Hlavaty, Michele Fusaroli, et al.
Drug Safety
|
March 17, 2026
9<sup>th</sup> ISoP Intelligent Automation Boston Seminar: From Innovation to Impact. Building Trustworthy AI in Pharmacovigilance 4-5 December 2025 | Cambridge, USA & Virtual
Omar Aimer, Tarek A Hammad, Jan Petracek, et al.
British Journal of Clinical Pharmacology
|
February 5, 2026
Through the lens of marketing authorization holders: experience in use of real-world data and real-world evidence in drug development and regulatory submissions in EU
Sini M Eskola, Aleksandar Gigov, Hubertus G M Leufkens, et al.
Drug Safety
|
April 30, 2024
Timing Matters: A Machine Learning Method for the Prioritization of Drug-Drug Interactions Through Signal Detection in the FDA Adverse Event Reporting System and Their Relationship with Time of Co-exposure
Vera Battini, Marianna Cocco, Maria Antonietta Barbieri, et al.
Pharmacoepidemiology and Drug Safety
|
May 10, 2002
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
Eugène P van Puijenbroek, Andrew Bate, Hubert G M Leufkens, et al.
Drug Safety
|
March 13, 2025
Off-the-Shelf Large Language Models for Causality Assessment of Individual Case Safety Reports: A Proof-of-Concept with COVID-19 Vaccines
Andrea Abate, Elisa Poncato, Maria Antonietta Barbieri, et al.
Page
of 11